Impax Laboratories $586 million acquisition of Teva/Allergan generic drug assets

Overview:

• Impax Laboratories has acquired a generic drug portfolio from Teva Pharmaceuticals and Allergan for $586 million.
• The portfolio consists of 15 marketed products.
• The deal is part of a divestiture effort to gain antitrust clearance by Teva, who acquired Dublin-based Allergan in July of last year.
• Sullivan & Cromwell (Frank Aquila, Matthew Hurd) and McDermott Will & Emery advised Impax.
• Kirkland & Ellis advised Teva.

Kurt Stumpo - Journalist - North America and the Caribbean